{"protocolSection": {"identificationModule": {"nctId": "NCT01542502", "orgStudyIdInfo": {"id": "HM14079"}, "organization": {"fullName": "Virginia Commonwealth University", "class": "OTHER"}, "briefTitle": "Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction", "officialTitle": "Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction"}, "statusModule": {"statusVerifiedDate": "2016-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-02"}, "primaryCompletionDateStruct": {"date": "2013-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-02-23", "studyFirstSubmitQcDate": "2012-03-01", "studyFirstPostDateStruct": {"date": "2012-03-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-08-19", "resultsFirstSubmitQcDate": "2016-03-04", "resultsFirstPostDateStruct": {"date": "2016-04-07", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-12-12", "lastUpdatePostDateStruct": {"date": "2017-02-06", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Virginia Commonwealth University", "class": "OTHER"}, "collaborators": [{"name": "American Heart Association", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This will be a randomized, double-blind, crossover pilot study to measure the safety and feasibility of Interleukin-1 (IL-1) blockade with Anakinra in patients with stable heart failure with preserved ejection fraction."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["Heart failure with preserved ejection fraction", "Diastolic heart failure", "Aerobic exercise performance"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 12, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Anakinra", "type": "EXPERIMENTAL", "description": "Treatment with daily subcutaneous injections of Anakinra 100 mg", "interventionNames": ["Drug: Anakinra"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Treatment with daily subcutaneous injection of placebo", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Anakinra", "description": "Anakinra 100 mg daily subcutaneous injection", "armGroupLabels": ["Anakinra"], "otherNames": ["Recombinant human Interleukin-1 receptor antagonist", "Kineret"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo daily subcutaneous injection", "armGroupLabels": ["Placebo"], "otherNames": ["Sodium Chloride (NaCl) 0.9%"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Peak Oxygen Consumption (Peak VO2)", "description": "The primary endpoint is the change in peak oxygen consumption among stable heart failure patients (n = 12) following 14-days treatment with daily doses of Anakinra 100 mg (SC, subcutaneous).", "timeFrame": "14 days"}], "secondaryOutcomes": [{"measure": "Exercise Time", "description": "Interval change from baseline in duration of exercise during a standardized cardiopulmonary exercise test upon completion of 2 weeks treatment", "timeFrame": "14 days"}], "otherOutcomes": [{"measure": "Correlation Between Endpoints", "description": "Correlation between interval change in peak VO2 and high sensitivity C-reactive protein", "timeFrame": "28 days"}, {"measure": "Heart Failure Symptoms (DASI)", "description": "Interval change from baseline in Heart Failure (HF) symptoms as measured by Duke Activity Status Index (DASI) upon completion of 2 weeks treatment.", "timeFrame": "28 days"}, {"measure": "Adverse Events", "description": "Additional endpoints will include assessment of adverse events and hospitalizations during 4-week duration of study.", "timeFrame": "28 days"}, {"measure": "Inflammatory Biomarkers", "description": "Interval change from baseline in high-sensitivity C-reactive protein upon completion of 2 weeks treatment.", "timeFrame": "28 days"}, {"measure": "Ventilatory Efficiency (VE/VCO2 [Carbon Dioxide] Slope)", "description": "Interval change from baseline in ventilatory efficiency (VE/VCO2 slope) upon completion of 2 weeks treatment.", "timeFrame": "14 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Symptoms and signs of congestive heart failure\n* Recent Imaging Study (\\<12 months) showing Left Ventricular Ejection Fraction (LVEF) \\>50% and Left Ventricular End Diastolic Volume Index (LVEDVI) \\<97ml/m2\n* Evidence of abnormal Left Ventricular (LV) relaxation, filling, diastolic distensibility, and diastolic stiffness as shown by one of the following:\n\n  1. Invasive Hemodynamic measurements\n\n     * mean Pulmonary Capillary Wedge pressure (mPCW) \\>12\n     * Left Ventricular End Diastolic Pressure (LVEDP) \\>16 mmHg\n  2. Tissue Doppler Echocardiogram\n\n     * E/E' \\>15\n     * E/E' 8-15 and one of the following\n\n       * Left Ventricular Hypertrophy (LVH)\n       * Atrial Fibrillation\n       * Left Atrial Enlargement\n       * E/A \\<0.5 + Deceleration Time (DT) \\>280 (if \\>50yrs of age)\n  3. Biomarkers\n* Brain Natriuretic Peptide (BNP) \\>200pg/mL\n\nExclusion Criteria:\n\n* Age \\<18\n* Recent changes (previous 3 months) in HF maintenance medications (beta-blockers, angiotensin converting enzyme \\[ACE\\] inhibitors, aldosterone antagonists, vasodilators, cardiac glycosides, diuretics)\n* Hospitalization for worsening Heart Failure (HF) or acute decompensated HF within the previous 12months\n* Anticipated need for cardiac resynchronization therapy (CRT) or automated-implantable cardioverter defibrillator (AICD)\n* Angina or electrocardiograph (ECG) changes that limit maximum exertion during cardiopulmonary exercise testing\n* Active infection including chronic infection\n* Active cancer\n* Recent (\\<14 days) use of anti-inflammatory drugs (not including Non-Steroidal Anti-Inflammatory Drugs \\[NSAIDs\\]), Chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus), malignancy, or any comorbidity limiting survival or ability to complete the study\n* Pregnancy (determined by urine pregnancy test in women of childbearing potential)\n* Inability to give informed consent\n* Other conditions limiting completion of cardiopulmonary exercise test or completion of the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Antonio Abbate, MD, PhD", "affiliation": "Virginia Commonwealth University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Virginia Commonwealth University", "city": "Richmond", "state": "Virginia", "zip": "23298", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Anakinra (First) Then Placebo (Second)", "description": "Treatment with daily subcutaneous injections of Anakinra 100 mg for 14 days, followed by daily subcutaneous injections of Placebo for 14 days\n\nAnakinra: Anakinra 100 mg daily subcutaneous injection Placebo: Placebo daily subcutaneous injection"}, {"id": "FG001", "title": "Placebo (First) Then Anakinra (Second)", "description": "Treatment with daily subcutaneous injections of Placebo for 14 days, followed by daily subcutaneous injections of Anakinra for 14 days\n\nPlacebo: Placebo daily subcutaneous injection Anakinra: Anakinra 100 mg daily subcutaneous injection"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "This is a cross-over trial, so all patients have been treated with anakinra and with placebo at different times.", "groups": [{"id": "BG000", "title": "All Participants", "description": "Baseline measures for all study participants"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "11"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "61", "lowerLimit": "55", "upperLimit": "64"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "11"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Peak Oxygen Consumption (Peak VO2)", "description": "The primary endpoint is the change in peak oxygen consumption among stable heart failure patients (n = 12) following 14-days treatment with daily doses of Anakinra 100 mg (SC, subcutaneous).", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "ml*kg^-1*min^-1", "timeFrame": "14 days", "groups": [{"id": "OG000", "title": "Anakinra", "description": "Treatment with daily subcutaneous injections of Anakinra 100 mg\n\nAnakinra: Anakinra 100 mg daily subcutaneous injection"}, {"id": "OG001", "title": "Placebo", "description": "Treatment with daily subcutaneous injection of placebo\n\nPlacebo: Placebo daily subcutaneous injection"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.1", "lowerLimit": "0.6", "upperLimit": "2.3"}, {"groupId": "OG001", "value": "-0.1", "lowerLimit": "-0.5", "upperLimit": "1.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.009", "statisticalMethod": "ANOVA", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Exercise Time", "description": "Interval change from baseline in duration of exercise during a standardized cardiopulmonary exercise test upon completion of 2 weeks treatment", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "minutes", "timeFrame": "14 days", "groups": [{"id": "OG000", "title": "Anakinra", "description": "Treatment with daily subcutaneous injections of Anakinra\n\nAnakinra: Anakinra 100 mg daily subcutaneous injection"}, {"id": "OG001", "title": "Placebo", "description": "Treatment with daily subcutaneous injection of placebo\n\nPlacebo: Placebo daily subcutaneous injection"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.05", "lowerLimit": "-0.05", "upperLimit": "0.85"}, {"groupId": "OG001", "value": "0.4", "lowerLimit": "0.025", "upperLimit": "0.925"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.87", "statisticalMethod": "ANOVA"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Correlation Between Endpoints", "description": "Correlation between interval change in peak VO2 and high sensitivity C-reactive protein", "reportingStatus": "NOT_POSTED", "timeFrame": "28 days", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Heart Failure Symptoms (DASI)", "description": "Interval change from baseline in Heart Failure (HF) symptoms as measured by Duke Activity Status Index (DASI) upon completion of 2 weeks treatment.", "reportingStatus": "NOT_POSTED", "timeFrame": "28 days", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Adverse Events", "description": "Additional endpoints will include assessment of adverse events and hospitalizations during 4-week duration of study.", "reportingStatus": "NOT_POSTED", "timeFrame": "28 days", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Inflammatory Biomarkers", "description": "Interval change from baseline in high-sensitivity C-reactive protein upon completion of 2 weeks treatment.", "reportingStatus": "NOT_POSTED", "timeFrame": "28 days", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Ventilatory Efficiency (VE/VCO2 [Carbon Dioxide] Slope)", "description": "Interval change from baseline in ventilatory efficiency (VE/VCO2 slope) upon completion of 2 weeks treatment.", "reportingStatus": "NOT_POSTED", "timeFrame": "14 days", "denomUnitsSelected": "Participants"}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "28 days", "eventGroups": [{"id": "EG000", "title": "Anakinra", "description": "Treatment with daily subcutaneous injections of Anakinra 100 mg\n\nAnakinra: Anakinra 100 mg daily subcutaneous injection", "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 3, "otherNumAtRisk": 12}, {"id": "EG001", "title": "Placebo", "description": "Treatment with daily subcutaneous injection of placebo\n\nPlacebo: Placebo daily subcutaneous injection", "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 0, "otherNumAtRisk": 12}], "otherEvents": [{"term": "Injection site reactions", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Mild injection site reaction - not requiring cessation of therapy", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 12}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "This is a pilot study to estimate the effects of targeted anti-inflammatory treatment on aerobic exercise capacity in patients with Heart Failure and Preserved Ejection Fraction. All findings should therefore be considered hypothesis generating."}, "certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Antonio Abbate", "organization": "Virginia Commonwealth University", "email": "aabbate@vcu.edu", "phone": "804-828-0513"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M27580", "name": "Heart Failure, Diastolic", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000053590", "term": "Interleukin 1 Receptor Antagonist Protein"}], "ancestors": [{"id": "D000018501", "term": "Antirheumatic Agents"}], "browseLeaves": [{"id": "M27359", "name": "Interleukin 1 Receptor Antagonist Protein", "asFound": "Cilgavimab", "relevance": "HIGH"}, {"id": "M20604", "name": "Antirheumatic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}